Next week could mark a significant period in the lengthy and continuing effort to help those suffering from Alzheimer’s. The federal Food and Drug Administration is expected to stamp its approval on a new medication, one looked to for slowing the progression of the memory-loss disease.
Dr. Greg Jicha describes the anticipated FDA approval of lecanemab as the first step toward a cure of Alzheimer’s. Jicha directs clinical trials at UK’s Sanders-Brown Center on Aging. The neurologist said the drug works to remove amyloid plaque from the brain. Jicha said it starts with knocking out this portion of Alzheimer’s and then to shift the focus.
